Systematic Analysis of the Aberrances and Functional Implications of Cuproptosis in Cancer

Overview

Journal iScience

Publisher Cell Press

Date 2023 Mar 23

PMID 36950125

Authors

Jiangbing Li

Boyan Li

Rongrong Zhao

Gang Li

Affiliations

Soon will be listed here.

Abstract

Cuproptosis is a novel form of cell death driven by a copper-dependent proteotoxic stress response whose comprehensive landscape in tumors remains unclear. Here, we comprehensively characterized cuproptosis-related genes (CRGs) across 33 cancers using multi-omic data from The Cancer Genome Atlas (TCGA), showing complicated and diverse results in different cancers. We also explored the relationships between CRGs and cancer metabolic patterns, pathway activity, and tumor microenvironment (TME), suggesting that they played critical roles in tumor progression and TME cell infiltration. We further established the cuproptosis potential index (CPI) to reveal the functional roles of cuproptosis, and characterized multi-omic molecular features associated with cuproptosis. In clinical applications, we performed a combined analysis of the sensitivity of CRGs and CPI to drug response and immunotherapy. This study provides a rich resource for understanding cuproptosis, offering a broad molecular perspective for future functional and therapeutic studies of multiple cancer pathways mediated by cuproptosis.

Citing Articles

Deng R, Zhu L, Jiang J, Chen J, Li H Biomol Biomed. 2023; 24(3):647-658.

PMID: 38041690 PMC: 11088889. DOI: 10.17305/bb.2023.9931.

Harnessing the Potential of Non-Apoptotic Cell Death Processes in the Treatment of Drug-Resistant Melanoma.

Dong L, Vargas C, Tian X, Chu X, Yin C, Wong A Int J Mol Sci. 2023; 24(12).

PMID: 37373523 PMC: 10299440. DOI: 10.3390/ijms241210376.

References

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Meric-Bernstam F, Gonzalez-Angulo A . Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13):2278-87. PMC: 2738634. DOI: 10.1200/JCO.2008.20.0766. View

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

Martinez-Reyes I, Chandel N . Cancer metabolism: looking forward. Nat Rev Cancer. 2021; 21(10):669-680. DOI: 10.1038/s41568-021-00378-6. View

Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F . Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017; 8(1):1738. PMC: 5701046. DOI: 10.1038/s41467-017-01460-0. View

Ge E, Bush A, Casini A, Cobine P, Cross J, DeNicola G . Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2021; 22(2):102-113. PMC: 8810673. DOI: 10.1038/s41568-021-00417-2. View

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

Bandmann O, Weiss K, Kaler S . Wilson's disease and other neurological copper disorders. Lancet Neurol. 2014; 14(1):103-13. PMC: 4336199. DOI: 10.1016/S1474-4422(14)70190-5. View

10.

Li J, Stanger B . How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy. Cancer Res. 2020; 80(19):4037-4041. PMC: 7541560. DOI: 10.1158/0008-5472.CAN-20-1420. View

11.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

12.

Tian Y, Morris T, Webster A, Yang Z, Beck S, Feber A . ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics. 2017; 33(24):3982-3984. PMC: 5860089. DOI: 10.1093/bioinformatics/btx513. View

13.

Tsvetkov P, Detappe A, Cai K, Keys H, Brune Z, Ying W . Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nat Chem Biol. 2019; 15(7):681-689. PMC: 8183600. DOI: 10.1038/s41589-019-0291-9. View

14.

Valipour M, Zarghi A, Ebrahimzadeh M, Irannejad H . Therapeutic potential of chelerythrine as a multi-purpose adjuvant for the treatment of COVID-19. Cell Cycle. 2021; 20(22):2321-2336. PMC: 8506812. DOI: 10.1080/15384101.2021.1982509. View

15.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

16.

Zhang J, Kong X, Zhang Y, Sun W, Wang J, Chen M . FDXR regulates TP73 tumor suppressor via IRP2 to modulate aging and tumor suppression. J Pathol. 2020; 251(3):284-296. PMC: 7748393. DOI: 10.1002/path.5451. View

17.

Nissan M, Pratilas C, Jones A, Ramirez R, Won H, Liu C . Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2014; 74(8):2340-50. PMC: 4005042. DOI: 10.1158/0008-5472.CAN-13-2625. View

18.

Zhang Q, Liu W, Zhang H, Xie G, Miao Y, Xia M . hTFtarget: A Comprehensive Database for Regulations of Human Transcription Factors and Their Targets. Genomics Proteomics Bioinformatics. 2020; 18(2):120-128. PMC: 7647694. DOI: 10.1016/j.gpb.2019.09.006. View

19.

Li J, Liu S, Zhou H, Qu L, Yang J . starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2013; 42(Database issue):D92-7. PMC: 3964941. DOI: 10.1093/nar/gkt1248. View

20.

Zhang C, Chen T, Li Z, Liu A, Xu Y, Gao Y . Depiction of tumor stemlike features and underlying relationships with hazard immune infiltrations based on large prostate cancer cohorts. Brief Bioinform. 2020; 22(3). DOI: 10.1093/bib/bbaa211. View